Information Provided By:
Fly News Breaks for June 23, 2015
ISIS
Jun 23, 2015 | 08:58 EDT
Needham raised its price target for Isis Pharmaceuticals to $91 from $88 saying it believes shares are not fully reflecting the recent SMA data. Investors may be confused about how sick Spinal Muscular Atrophy patients are, the firm tells investors. It adds that ISIS-SMNRx has combined survival improvements with "meaningful" functional improvements. Needham keeps a Buy rating on Isis.
News For ISIS From the Last 2 Days
There are no results for your query ISIS
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.